Literature DB >> 10817605

Sedative effects of the dopamine D1 receptor agonist A 68930 on rat open-field behavior.

P Salmi1, S Ahlenius.   

Abstract

The present results demonstrate sedative effects of the DA D1 receptor agonist A 68930 (0.9-15 micromol kg(-1), s.c.) on rat spontaneous locomotor activity in an open field. The effects were particularly strong, and dose-dependent, for the ambulatory activity in the open-field arena (forward locomotion) and for rearing activity, whereas the suppression of locomotor activity (i.e. total horizontal activity in the open field) was less conspicuous. The distribution of activity within the open field (activity in center vs periphery) was not consistently affected by the A 68930 treatment. In support for DA D1 receptor mediated effects of A 68930, the effects on locomotor activity, forward locomotion, and on rearing behavior, were partially antagonized by the DA D1 receptor antagonist SCH 23390 (15 nmol kg(-1) s.c.). SCH 23390 by itself produced a modest, but statistically significant, suppression of these different items of open-field behavior. The atypical antipsychotic agent clozapine has previously, in this laboratory, been shown to stimulate DA D1 receptors in vivo. There are a number of clinical and laboratory observations, consistent with the notion of a beneficial role for such effects in schizophrenia. Thus, the sedation, apparently not related to extrapyramidal motor functions, produced by DA D1 receptor agonist A 68930 could reflect an important aspect of the mechanism of action for atypical antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817605     DOI: 10.1097/00001756-200004270-00025

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  7 in total

1.  D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex.

Authors:  Yang Yang; Sang-Min Lee; Fumiaki Imamura; Krishne Gowda; Shantu Amin; Richard B Mailman
Journal:  Mol Psychiatry       Date:  2018-12-07       Impact factor: 15.992

2.  Differential response of central dopaminergic system in acute and chronic unpredictable stress models in rats.

Authors:  Naila Rasheed; Ausaf Ahmad; Chandra Prakash Pandey; Rajnish Kumar Chaturvedi; Mohtashim Lohani; Gautam Palit
Journal:  Neurochem Res       Date:  2009-07-01       Impact factor: 3.996

3.  A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.

Authors:  Silke Nuber; Florian Harmuth; Zacharias Kohl; Anthony Adame; Margaritha Trejo; Kai Schönig; Frank Zimmermann; Claudia Bauer; Nicolas Casadei; Christiane Giel; Carsten Calaminus; Bernd J Pichler; Poul H Jensen; Christian P Müller; Davide Amato; Johannes Kornhuber; Peter Teismann; Hodaka Yamakado; Ryosuke Takahashi; Juergen Winkler; Eliezer Masliah; Olaf Riess
Journal:  Brain       Date:  2013-02       Impact factor: 13.501

4.  Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation and protects rats from spinal cord injury-induced acute lung injury.

Authors:  W Jiang; M Li; F He; Z Bian; J Liu; Q He; X Wang; T Sun; L Zhu
Journal:  Spinal Cord       Date:  2016-04-12       Impact factor: 2.772

5.  Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.

Authors:  Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

6.  Differential effects of a selective dopamine D1-like receptor agonist on motor activity and c-fos expression in the frontal-striatal circuitry of SHR and Wistar-Kyoto rats.

Authors:  Rochellys Diaz Heijtz; F Xavier Castellanos
Journal:  Behav Brain Funct       Date:  2006-05-26       Impact factor: 3.759

Review 7.  Role of pyroptosis in spinal cord injury and its therapeutic implications.

Authors:  Abdullah Al Mamun; Yanqing Wu; Ilma Monalisa; Chang Jia; Kailiang Zhou; Fahad Munir; Jian Xiao
Journal:  J Adv Res       Date:  2020-08-18       Impact factor: 10.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.